Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 73
Selected: 0
NCT IDTitle
NCT05840510Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
NCT02978859Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
NCT06801418Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets
NCT05542342Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
NCT05924152A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
NCT04772612A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT07723118A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent
NCT03606174A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
NCT05255276PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
NCT03575598Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
NCT05578092A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
NCT03994796Genetic Testing in Guiding Treatment for Patients With Brain Metastases
NCT05263986The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
NCT05853575Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT06026410KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT04123704Sitravatinib in Metastatic Breast Cancer
NCT02544633Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
NCT00511576Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
NCT00358982Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT02664935National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
NCT05375994Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
NCT04685135Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT03680521Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
NCT00975767A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
NCT02219711Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
NCT00324220A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
NCT00431873A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
NCT00359086Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
NCT04418661Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
NCT05634525Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
NCT00697632Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
NCT04330664Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
NCT05419817Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
NCT00323934Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT06039384A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
NCT02236195Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
NCT04975256Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
NCT04800614A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib
NCT06130254Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
NCT00324194A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
NCT04793958Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT03785249Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT00374296MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
NCT05737706Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
NCT02117245Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers
NCT00666497Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT01930006Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
NCT00372437A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
NCT05472623Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
NCT05868356A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib